After all the recent news about the PSA test, here's a genomics answer. The MD Anderson Cancer Center, demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells. The new prostate cancer test will be performed at Clarient's Clinical...
Posted to
The Medical Quack .... by Barbara Duck
on 08-07-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, personalized medicine, DNA, Genomics, Prostate Cancer, Pharmacogenomics, PSA, Cancer Test
The software offers both detailed, localized views of genomic data, and a whole genome view, in a format somewhat similar to the way Google presents items on the web. It is free to download and use. There are also some sample data files available. I like the idea of the heat map view...
Posted to
The Medical Quack .... by Barbara Duck
on 08-06-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Other Items of Interest, DNA, Genomics, Research, Pharmacogenomics, MIT, Biomed, Broad Institute, Harvard
The program uses just plain old Java, but add this technology with sequencing information and with the 4D applications, studies can be virtually conducted to see how a medication would react with selected settings. Its resolution is scaleable to 100,000,000 pixels and more by using more than one...
Posted to
The Medical Quack .... by Barbara Duck
on 08-05-2008
Filed under: Medically Related, Technology, Pharma/FDA News, DNA, Genomics, Research, Pharmacogenomics, Biomed, Disease, Virtual Reality
This is good, a genomics test that can give some preliminary results on whether or not statins will have an adverse effect before prescribing them. As the post states here, this is something that could certainly use some marketing to physicians. Zocor at 40 mg is a very common dosage and...
One CEO comes out and states how biotech will be the new focus for Glaxo, as in a related story whereby patients will require genetic testing for their AIDS drug, Ziagen. In the future I’m sure there will be more about big pharma and their biotech strategies as personalized medicine continues...
Not too many years ago I remembered hearing the term “hospitalist” and asked what’s that? The hospitalist has evolved and is now one of the top growing professions. With Pharmacogenomics, we might be on the verge of a new specialty, a “Longevity Doctor”. We already have a dwindling...
Posted to
The Medical Quack .... by Barbara Duck
on 07-20-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Physician, DNA, Genomics, healthcare, Pharmacogenomics, Medical School, Personalized Mediince
The National Institute of Health sees the value of genetic profiles and is funding additional research. Duke University was the first client to use Expression Analysis and collaborates with the FDA and pharma for electronic submissions of data in an effort to accelerate drugs and diagnostics though...